Refresh Page for recalculating.
The IPSS, first published in 1997 and subsequently validated, has become the most widely adopted predictor of prognosis for patients with MDS.
The + points of IPSS include:-
-  Its simplicity and that it does not require any testing beyond the routine diagnostic evaluation.
-  Standard for describing populations of patients participating in pivotal clinical trials for MDS, including those that led to the approval of lenalidomide, azacitidine, and decitabine in most countries around the world.
-  IPSS is explicitly used by clinical guidelines such as those published by the National Comprehensive Cancer Network (NCCN) to help inform the choice of therapy for MDS patients.
These features have allowed the IPSS to remain the standard of reference even as subsequent prognostic scoring systems have been developed to address some of its weaknesses.
Click here for Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment.
OTHER RISK GROUP -PROGNOSTIC SCORING
-  WHO-based Prognostic Scoring System (WPSS)
-  Lower-Risk MDS Prognostic Scoring System (LR-PSS)
-  MD Anderson Comprehensive Scoring System (MDA-CSS)